CIBC Private Wealth Group
ACRS icon

CIBC Private Wealth Group’s Aclaris Therapeutics ACRS Stock Holding History

CIBC Private Wealth Group’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-10,000
Closed -$200K – 970
2018
Q2 		$200K Buy
+10,000
New +$185K ﹤0.01% 920

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

CIBC Private Wealth Group's ACRS Position: Q3 2018 in Review

CIBC Private Wealth Group sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 10,000 shares — an estimated $200K sold.

CIBC Private Wealth Group first reported a position in ACRS in Q2 2018 and held it in 1 quarter. The position peaked at $200K in Q2 2018. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

  • CIBC Private Wealth Group reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
  • CIBC Private Wealth Group sold 10,000 Aclaris Therapeutics shares in Q3 2018, an estimated $200K.
  • CIBC Private Wealth Group first reported a position in Aclaris Therapeutics in Q2 2018 and held it in 1 quarter.
  • CIBC Private Wealth Group's Aclaris Therapeutics position peaked at $200K in Q2 2018.
  • 86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on CIBC Private Wealth Group's 13F filing for Q3 2018, filed 14 Nov 2018.